Risque hémorragique et anti-angiogéniques

25 mars 2010

Auteurs : J. Ayllon, G. Pignot
Référence : Prog Urol, 2010, 20, S20, suppl. S1


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser


Folkman J. Tumor angiogenesis: therapeutic implications N Engl J Med 1971 ;  285 : 1182-1186
Méjean A., Lebret T. Angiogénèse : le modèle du cancer du rein Prog Urol 2008 ;  18 : S309-S314
Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases Nature 2000 ;  407 : 249-257 [cross-ref]
Rini B.I. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma Cancer 2009 ;  115 : 2306-2312 [cross-ref]
Elice F., Jacoub J., Rickles F.R., Falanga A., Rodeghiero F. Hemostatic complications of angiogenesis inhibitors in cancer patients Am J Hematol 2008 ;  83 : 862-870 [cross-ref]
Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., McDonald D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 Science 1999 ;  286 : 2511-2514 [cross-ref]
Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome Nat Rev Cancer 2002 ;  2 : 673-682 [cross-ref]
Carden C.P., Larkin J.M., Rosenthal M.A. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 2008 ;  10 : 624-630 [cross-ref]
Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor, in patients with metastatic renal cell carcinoma J Clin Oncol 2006 ;  24 : 16-24 [cross-ref]
Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 2006 ;  24 : 2505-2512 [cross-ref]
Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bévacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 2007 ;  370 : 2103-2111 [cross-ref]
Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo-controlled phase III trial Lancet 2008 ;  372 : 449-456 [cross-ref]
Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bévacizumab J Surg Oncol 2005 ;  91 : 173-180 [cross-ref]
Bhojani N., Jeldres C., Patard J.J., Perrotte P., Suardi N., Hutterer G., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma Eur Urol 2008 ;  53 : 917-930 [cross-ref]

© 2010 
Elsevier Masson SAS. Tous droits réservés.